Cebranopadol as a Novel Promising Agent for the Treatment of Pain

12Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Opioids are used to treat pain, but despite their effectiveness, they possess several side effects such as respiratory depression, tolerance and physical dependence. Cebranopadol has been evaluated as a solution to this problem. The compound acts on the mu opioid receptor and the no-ciceptin/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management.

Cite

CITATION STYLE

APA

Ziemichod, W., Kotlinska, J., Gibula-Tarlowska, E., Karkoszka, N., & Kedzierska, E. (2022, July 1). Cebranopadol as a Novel Promising Agent for the Treatment of Pain. Molecules. MDPI. https://doi.org/10.3390/molecules27133987

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free